Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years

被引：0
|
作者：
Horinouchi, H. [1 ]
Ohe, Y. [1 ]
Yamanaka, Y. [2 ]
Kurata, T. [2 ]
Watanabe, K. [3 ]
Hosomi, Y. [3 ]
Nakahara, Y. [4 ]
Asao, T. [5 ]
Saeki, S. [6 ]
Tsubata, Y. [7 ]
Fujita, Y. [8 ]
Konishi, J. S. [9 ]
Mizugaki, H. [10 ]
Ohuchi, M. [11 ]
Yagishita, S. [11 ]
Hamada, A. [11 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Kansai Med Univ Hosp, Osaka, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[4] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[5] Juntendo Univ Hosp, Tokyo, Japan
[6] Kumamoto Univ Hosp, Kumamoto, Japan
[7] Shimane Univ, Fac Med, Matsue, Shimane, Japan
[8] Jikei Univ, Sch Med, Tokyo, Japan
[9] Hokkaido Univ, Fac Med, Sapporo, Hokkaido, Japan
[10] JFCR, Canc Inst Hosp, Tokyo, Japan
[11] Natl Canc Ctr, Res Inst, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Pembrolizumab; pharmacokinetics; Elderly;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.03-08
引用
收藏
页码：S622 / S622
页数：1
相关论文
共 50 条
  • [31] Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply
    Asahina, Hajime
    Tsukita, Yoko
    Tozuka, Takehiro
    JAMA ONCOLOGY, 2024, 10 (12) : 1732 - 1733
  • [32] Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
    Elias, Rawad
    Morales, Joshua
    Presley, Carolyn
    CURRENT ONCOLOGY REPORTS, 2017, 19 (09)
  • [33] Non-small cell lung cancer in adults under 40 years of age
    Lemaire, M.
    Durieux, V.
    Meert, A. -p.
    Berghmans, T.
    REVUE DES MALADIES RESPIRATOIRES, 2024, 41 (10) : 727 - 737
  • [34] Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older
    Saito, Zentaro
    Fujita, Kohei
    Okamura, Misato
    Ito, Takanori
    Yamamoto, Yuki
    Kanai, Osamu
    Hashimoto, Masayuki
    Nakatani, Koichi
    Sawai, Satoru
    Mio, Tadashi
    CANCER REPORTS, 2021, 4 (06)
  • [35] Stage I Non-small Cell Lung Cancer (NSCLC) in Patients Aged 75 Years and Older Does Age Determine Survival After Radical Treatment?
    Palma, David A.
    Tyldesley, Scott
    Sheehan, Finbarr
    Mohamed, Islam G.
    Smith, Sally
    Wai, Elaine
    Murray, Nevin
    Senan, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 818 - 824
  • [36] The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer
    Mazarico Gallego, Jose Ma
    Herrera Juarez, Mercedes
    Paz-Ares, Luis
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 233 - 242
  • [37] Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
    Vachhani, Pankit
    Chen, Hongbin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5855 - 5866
  • [38] East Anglian audit of pembrolizumab in non-small cell lung cancer
    Jackson, A. H.
    Fenn, R.
    Shotton, R.
    Williams, A.
    Treece, S.
    Gkogkou, P.
    Tasigiannopoulos, Z.
    Gilligan, D.
    Yip, K.
    LUNG CANCER, 2018, 115 : S39 - S39
  • [39] Pembrolizumab toxicity in non-small cell lung cancer: a retrospective analysis
    Keast, Mary
    Button, Mick
    Case, Amy
    Iqbal, Sahar
    Namelo, Clara
    Powell, Ceri
    Powell, James
    Shaw, Paul
    Cox, Samantha
    LUNG CANCER, 2022, 165 : S37 - S38
  • [40] Stereotactic Body Radiotherapy in Patients With Stage I Non-Small-Cell Lung Cancer Aged 75 Years and Older: Retrospective Results From a Multicenter Consortium
    Samuels, Michael A.
    Kandula, Shravan
    Koru-Sengul, Tulay
    Bogart, Jeffrey A.
    Salama, Joseph K.
    Aridgides, Paul D.
    Gajra, Ajeet
    Lilenbaum, Rogerio C.
    CLINICAL LUNG CANCER, 2013, 14 (04) : 446 - 451
12345